$ZBH

ZIMMER BIOMET HOLDINGS, INC.

Zimmer Biomet designs, manufactures and markets medical technology for patients with disorders or injuries affecting bones, joints and supporting soft tissues. Its customers include orthopedic and neurosurgeons, other specialists, hospitals, ambulatory surgery centers, distributors and healthcare dealers. The company is headquartered in Warsaw, Indiana. Its products include knee and hip implants; sports medicine, biologics, foot and ankle, upper-extremity, trauma and craniomaxillofacial and thoracic products; bone cement; surgical solutions; and digital and robotic technologies. Brands include Persona, NexGen, Taperloc, JuggerKnot and the ROSA Robot. The ZBEdge Platform connects digital and robotic technologies to collect data before, during and after surgery. Zimmer Biomet sells directly to healthcare institutions and through stocking distributors and healthcare dealers, with consignment sales representing approximately 85 percent of net sales in 2025. It operates in the Americas, EMEA and Asia Pacific.

AlphAI earnings readthird quarter 2026 · NOV 4Zimmer Biomet Announces Third Quarter 2026 Financial ResultsVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

4
0
2

No SEC Form 4 filings for $ZBH in the last 30 days.

See all $ZBH insider activity →

BMO cuts Zimmer Biomet stock price target on debt refinancing costs

BMO Capital reduced its price target for Zimmer Biomet (ZBH) to $101 from $102, citing higher debt refinancing costs. The company issued €500M and $500M in notes, adding ~$17M in annual interest expense. ZBH's Q3 2026 revenue was $2.06B, beating estimates, with EPS flat at $1.90. Analysts adjusted targets, with Stifel at $140 and Jefferies at $120.

ZBH sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning ZBH (ZIMMER BIOMET HOLDINGS, INC.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 2 bearish.

Recent ZBH coverage spans financial news, market movers and corporate actions.

What's driving ZBH

AlphAI scores every news story that mentions ZBH with an AI model for sentiment and relevance, and aggregates insider trades from ZIMMER BIOMET HOLDINGS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ZBH

Score
$ZBHHighDebt financing· €500M

ZIMMER BIOMET HOLDINGS, INC. (ZBH): Entry into a Material Definitive Agreement

ZIMMER BIOMET HOLDINGS, INC. (ZBH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 5, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “EUR Underwriting Agreement”) with Barclays Bank PLC, Citigroup Global Markets Limited, HSBC Bank plc, Morgan Stanle

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

Related tickers